Autolus Therapeutics plc financial data

Symbol
AUTL on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
The Mediaworks, 191 Wood Lane, London, United Kingdom
State of incorporation
United Kingdom
Fiscal year end
December 31
Former names
Autolus Therapeutics Ltd (to 6/8/2018)
Latest financial report
Q1 2024 - May 17, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.04 K % +29.4%
Debt-to-equity 93.4 % +49.8%
Return On Equity -80.2 % -24.5%
Return On Assets -41.5 % -4.51%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 266 M shares
Entity Public Float 279 M USD
Weighted Average Number of Shares Outstanding, Basic 222 M shares +27.8%
Weighted Average Number of Shares Outstanding, Diluted 222 M shares +27.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 134 M USD +14.9%
General and Administrative Expense 55.6 M USD +67.6%
Operating Income (Loss) -179 M USD -22.5%
Nonoperating Income (Expense) -42 M USD -751%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -221 M USD -46.2%
Income Tax Expense (Benefit) -13.5 K USD -105%
Net Income (Loss) Attributable to Parent -221 M USD -46%
Earnings Per Share, Basic -1.21 USD/shares +13%
Earnings Per Share, Diluted -1.21 USD/shares +13%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 759 M USD +121%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD
Other Assets, Current 0 USD -100%
Assets, Current 804 M USD +104%
Deferred Income Tax Assets, Net 3.3 M USD +45%
Property, Plant and Equipment, Net 33.4 M USD -3.61%
Operating Lease, Right-of-Use Asset 59.1 M USD +120%
Assets 901 M USD +96%
Accounts Payable, Current 1.4 M USD +296%
Employee-related Liabilities, Current 11.3 M USD
Accrued Liabilities, Current 37.8 M USD +9.59%
Liabilities, Current 44 M USD +11%
Contract with Customer, Liability, Noncurrent 228 M USD +74.7%
Operating Lease, Liability, Noncurrent 46.5 M USD +107%
Other Liabilities, Noncurrent 409 K USD +259%
Liabilities 319 M USD +65.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -28.9 M USD +13%
Retained Earnings (Accumulated Deficit) -931 M USD -31.2%
Stockholders' Equity Attributable to Parent 582 M USD +118%
Liabilities and Equity 901 M USD +96%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -40.5 M USD +4.49%
Net Cash Provided by (Used in) Financing Activities 561 M USD
Net Cash Provided by (Used in) Investing Activities -533 K USD +85.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 519 M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 760 M USD +121%
Deferred Tax Assets, Valuation Allowance 123 M USD +28.1%
Deferred Tax Assets, Gross 126 M USD +28.6%
Operating Lease, Liability 51.3 M USD
Depreciation 1.8 M USD -5.26%
Payments to Acquire Property, Plant, and Equipment 533 K USD -85.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -217 M USD -28.5%
Lessee, Operating Lease, Liability, to be Paid 87.9 M USD
Operating Lease, Liability, Current 4.82 M USD -0.06%
Lessee, Operating Lease, Liability, to be Paid, Year Two 6.61 M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 6.84 M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure +14.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 36.6 M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 6.47 M USD
Deferred Tax Assets, Operating Loss Carryforwards 105 M USD +30.3%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.75 M USD
Operating Lease, Payments 1.73 M USD +33.1%
Additional Paid in Capital 1.54 B USD +52.7%
Depreciation, Depletion and Amortization 1.81 M USD -4.9%
Share-based Payment Arrangement, Expense 2.28 M USD -5.46%
Interest Expense 59.4 M USD +394%